13F Holdings
中文EN

RGEN REPLIGEN CORP

Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 730272 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY13.8%
TTM net income YoY-779.2%
TTM EPS YoY-1,150.0%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin53.8%
Operating margin2.3%
Net margin-1.5%
FCF margin13.2%
EBITDA margin11.9%

Returns

ROE-0.6%
ROA-0.4%
ROIC (approx.)0.5%
Asset turnover0.28x

Leverage & solvency

Liabilities / assets28.5%
Debt / equity0.27x
Current ratio9.88x
Interest coverage0.81x

Cash quality & payout

Operating cash flow / net income-11.00x
Accruals ratio-4.8%
Payout ratio—
Capex / revenue2.9%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31FY20232023-12-31FY20222022-12-31FY20212021-12-31
Income statement
Revenue$738.26M$634.44M$632.36M$801.54M$670.53M
Cost of revenue$352.01M$359.79M$353.92M$345.83M$279.28M
Gross profit$386.25M$274.64M$278.44M$455.71M$391.25M
R&D expense$54.18M$43.20M$42.72M$43.94M$34.27M
SG&A expense$290.51M$263.37M$218.58M$215.83M$183.87M
Operating income$55.17M-$35.11M$47.70M$224.67M$167.25M
Interest expense$21.51M$20.73M$2.50M$1.16M$11.28M
Pretax income$62.38M-$27.04M$56.71M$219.14M$153.54M
Income tax$13.49M-$1.52M$21.11M$33.18M$25.25M
Net income$48.89M-$25.51M$35.60M$185.96M$128.29M
EBITDA$133.91M$34.56M$116.26M$275.65M$205.70M
EPS (basic)0.87-0.460.643.352.33
EPS (diluted)0.86-0.460.633.242.24
Weighted avg. shares (diluted)56,56155,93756,37757,45557,264
Balance sheet
Cash & equivalents$566.02M$757.36M$751.32M$523.46M$603.81M
Short-term investments$201.61M$0———
Receivables$158.59M$134.12M$124.16M$116.25M$117.42M
Inventory$170.46M$142.96M$202.32M$238.28M$184.49M
Current assets$1.14B$1.07B$1.11B$998.12M$931.68M
PP&E, net$186.61M$197.74M$207.44M$190.67M$124.96M
Goodwill$1.11B$1.03B$987.12M$855.51M$860.36M
Intangibles$386.15M$397.90M$406.96M$360.62M$337.27M
Total assets$2.95B$2.83B$2.83B$2.53B$2.36B
Current liabilities$135.83M$126.79M$164.94M$404.20M$375.26M
Long-term debt$542.21M$525.57M———
Total debt$542.21M$525.57M———
Total liabilities$843.57M$856.95M$866.34M$620.90M$608.29M
Shareholders' equity$2.11B$1.97B$1.96B$1.91B$1.75B
Net debt-$23.81M-$231.79M———
Shares outstanding56.33M56.09M55.77M55.56M55.32M
Cash flow statement
Operating cash flow$117.42M$175.39M$113.92M$172.08M$119.02M
Capital expenditure$23.52M$25.68M$36.22M$84.83M$67.09M
Free cash flow$93.90M$149.72M$77.70M$87.25M$51.93M
Investing cash flow-$298.47M-$86.38M-$123.28M-$233.24M-$221.17M
Financing cash flow-$15.21M-$82.90M$248.96M-$13.34M$961,000
Depreciation & amortization$78.75M$69.67M$68.56M$50.98M$38.45M
Stock-based compensation$32.60M$48.07M$25.57M$27.32M$27.50M
Share buybacks$0$0$14.39M$0$0

Free plan shows the latest 5 periods; Pro shows all 17 🔒

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.